Epizyme Inc (NASDAQ:EPZM)

2.93
Delayed Data
As of 4:00pm ET
 -0.345 / -10.55%
Today’s Change
2.93
Today|||52-Week Range
14.30
-73.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$350.1M

Company Description

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Contact Information

Epizyme, Inc.
400 Technology Square
Cambridge Massachusetts 02139
P:(617) 229-5872
Investor Relations:

Employees

Shareholders

Other institutional41.15%
Mutual fund holders40.63%
Individual stakeholders29.37%

Top Executives

Grant C. BoglePresident, Chief Executive Officer, CFO & Director
Shefali AgarwalExecutive VP, Chief Medical & Development Officer
Jeffery L. KutokChief Scientific Officer & Executive VP
John F. WeidenbruchSecretary, Senior Vice President & General Counsel
Aidan FinleyDirector-Business Development